Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 10/20 | 0.40 |
| ▸ | KDM6B | O15054 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4A | O75164 | 2/20 | 0.39 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3812402 | 0.85 | TDP1 (0.59) | TDP1SIRT3GSK3BKDM4CKDM6B | |
| Hydrochloric Acid SCHEMBL641566 | 0.84 | TDP1 (0.58) | TDP1SIRT3GSK3BKDM4CKDM6B | |
| Bromide SCHEMBL5567775 | 0.84 | TDP1 (0.58) | TDP1SIRT3GSK3BKDM4CKDM6B | |
| SCHEMBL16684319 | 0.80 | KDM4C (0.41) | TDP1SIRT3GSK3BKDM4CKDM6B | |
| SCHEMBL31438505 | 0.79 | CCNC (0.41) | TDP1SIRT3GSK3BKDM4CKDM6B | |
| SCHEMBL1883873 | 0.79 | CCNC (0.41) | TDP1SIRT3GSK3BKDM4CKDM6B | |
| Bromide SCHEMBL16671695 | 0.79 | KDM4C (0.40) | TDP1SIRT3GSK3BKDM4CKDM6B | |
| SCHEMBL22286141 | 0.78 | GSK3B (0.41) | TDP1GSK3BKDM4CKDM6BKDM4E | |
| SCHEMBL4185590 | 0.78 | PTPN1 (0.41) | TDP1SIRT3GSK3BKDM4CKDM6B | |
| SCHEMBL29701774 | 0.78 | PTPN1 (0.41) | TDP1SIRT3GSK3BKDM4CKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315881-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140315881-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140315881-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-10-23 | — | — | US | disclosed |
| EP-2736330-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013019682-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2013019682-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2013019626-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| WO-2009114552-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | VHL, TP53, BECN1 | TDP1 1160/4885SIRT3 2243/4885GSK3B 1153/4885 |
| US-20140315881-A1 | COMPOUNDS AND METHODS | RORC, RORB, RORA | TDP1 4487/4885SIRT3 1602/4885GSK3B 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.